---
search:
  boost: 3
---
# Medication Assisted Treatment of Opioid Addiction

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [Medication Assisted Treatment of Opioid Addiction - Buprenorphine](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUODI2WDdYQTlKUlY3MkxUNjIzVTEzOVROTCQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Medication Assisted Treatment of Opioid Addiction - Lucemyra](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNzBLTExYQTlGTVFXUFZRWVpUWDNUNEFJRiQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                | Generic Name                                      | Quantity | Time (Days) |
| :----------------------- | :------------------------------------------------ | :------: | :---------: |
| Buprenorphine / Naloxone |                                                   |          |             |
| Clonidine                |                                                   |          |             |
| Sublocade <sup>QL</sup>  | Buprenorphine ER Subcutaneous Inj 100 MG / 0.5 ML |   0.5    |     30      |
| Sublocade <sup>QL</sup>  | Buprenorphine ER Subcutaneous Inj 300 MG / 1.5 ML |   1.5    |     30      |
| Suboxone                 |                                                   |          |             |
| Vivitrol                 | Naltrexone ER Susp IM Inj (all strengths)         |    1     |     28      |
| Zubsolv                  |                                                   |          |             |

### Non-Preferred

| Non-Preferred          | Generic Name                   |         Quantity          |        Time (Days)        |
| :--------------------- | :----------------------------- | :-----------------------: | :-----------------------: |
| Buprenorphine          |                                |                           |                           |
| Lucemyra <sup>QL</sup> | Lofexidine Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations**: 180 days except 14 days for Lucemyra

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Lofexidine (Lucemyra)

Additional Lofexidine (Lucemyra) Criteria

- May be authorized if ALL of the following criteria are met:
  - Must provide medical justification supporting why an opioid taper (such as with buprenorphine or methadone) cannot be used
  - Must have had an inadequate clinical response or contraindication to clonidine
- Must provide documentation that the drug was initiated in an inpatient setting to be exempt from the above criteria

### Buprenorphine

Buprenorphine Safety Edits and Drug Utilization Review Criteria

- Prescribing for buprenorphine products must follow the requirements of Ohio Administrative Code rule 4731-33-03 Office based treatment for opioid addiction.
- In favor of eliminating prior authorization for all forms of oral short acting buprenorphine- containing products, ODM and the Managed Care Plans will implement safety edits and a retrospective drug utilization review processfor all brand and generic forms of oral short acting buprenorphine-containing products. Safety edits are in place for dosages over 24mg of buprenorphine equivalents/day.
- Buprenorphine sublingual tablets (generic Subutex) will be restricted to pregnancy, breastfeeding, or contraindication to preferred products
- Buprenorphine injection (Sublocade) dosing schedule will be limited to 300mg/30 days

### Additional Information

- Vivitrol and Sublocade may be billed by the pharmacy if it is not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider's staff, following all regulationsfor a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy.


### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=39){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=16){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
